JPMorgan Chase & Co vs Medtronic PLC — how do they compare? JPMorgan Chase & Co trades at $361.82 (market cap $956.39B), while Medtronic PLC trades at $90.48 (market cap $114.45B). The key difference: JPMorgan Chase & Co is far larger — about 8.4× Medtronic PLC's market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.
| JPM | MDT | |
|---|---|---|
Market Cap | $956.39B | $114.45B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $362.04 | $105.35 |
52-Week Low | $282.84 | $73.75 |
Dividend Yield | 1.67% | 3.22% |
Enterprise Value | — | $133.19B |
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings show a Q2 2026 beat ($7.59 actual vs. $5.59 expected), though Q4 2025 missed estimates. Revenue grew to $181.85B in 2025, with a net income margin of 33.38% and ROE of 18.43%, but cash flow trends remain volatile with negative net cash flow in 2025.
The outlook is positive with strong profitability and analyst support, but risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI advancements. The stock offers upside to the price target, yet investors should monitor cash flow stability and macroeconomic headwinds highlighted by CEO Jamie Dimon's recent warnings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →